Triple Hair Initiates Phase III Trial for TH07 Triple-Combination Therapy in Male Pattern Baldness
核心洞察
Triple Hair Group has dosed the first patient in its Phase III clinical trial evaluating TH07, a patented triple-combination topical therapy for male androgenic alopecia (搜索).
The 24-week randomized, double-blind, placebo-controlled study will enroll 420 men with moderate to moderately advanced androgenic alopecia (搜索) across up to 10 Canadian clinical sites.
TH07 combines minoxidil, finasteride, and latanoprost in a single topical spray formulation, targeting multiple biological pathways involved in hair loss.
Triple Hair Group Inc. (搜索) has achieved a significant milestone in its development of innovative androgenic alopecia (搜索) treatments, announcing the dosing of the first patient in its Phase III clinical trial evaluating TH07, a patented prescription topical therapy for male pattern hair loss. The Canadian biotechnology company's pivotal study represents a major advancement in addressing a condition that affects hundreds of millions of men worldwide.
Phase III Trial Design and Scope
The Phase III clinical trial (NCT07435012) is designed as a 24-week, randomized, double-blind, placebo-controlled, multicentre study that will evaluate the safety and efficacy of TH07 in men with androgenic alopecia (搜索). The study is expected to enroll 420 male participants with moderate to moderately advanced androgenic alopecia across up to 10 clinical sites in Canada.
"The dosing of the first patient in our Phase III trial marks an important milestone for Triple Hair and the continued advancement of TH07," said Jean-Philippe Gravel, President and CEO of Triple Hair. "Androgenic alopecia (搜索) affects hundreds of millions of men globally and remains an area of significant unmet need, with limited effective treatment options available. We believe TH07's differentiated multi-mechanism approach has the potential to offer a meaningful new prescription treatment option in a large and underserved market."
TH07's Multi-Mechanism Approach
TH07 represents a novel approach to treating male pattern baldness (搜索) through its patented prescription topical spray formulation that combines three active ingredients: minoxidil, finasteride, and latanoprost. Each component has demonstrated relevance to hair-growth biology through approved use and published scientific literature, targeting distinct biological pathways involved in androgenic alopecia (搜索).
The therapy is specifically designed to address multiple mechanisms associated with hair loss by stimulating hair follicle (搜索) activity, reducing androgen-mediated follicle miniaturization, and supporting prolonged hair growth cycles. By integrating these complementary mechanisms in a single topical formulation, TH07 simultaneously targets several key drivers of hair loss.
Promising Early Clinical Results
TH07 has demonstrated encouraging results in earlier clinical studies, with 82% of participants experiencing positive outcomes ranging from moderate to dense hair regrowth. These results have supported the therapy's continued development and advancement to Phase III evaluation.
Dr. Martin Braun, Principal Medical Investigator of Triple Hair's Phase III trial, emphasized the clinical significance of the study. "Male pattern baldness (搜索) remains one of the most common dermatological conditions affecting men," he noted. "This study is expected to provide important data on whether a multi-mechanism topical therapy such as TH07 can improve treatment outcomes for patients."
Market Context and Unmet Need
The global hair-loss treatment market was valued at approximately US$8.8 billion in 2023 and is projected to reach over US$16 billion by 2030, reflecting the significant demand for safe and effective treatment options. This growth trajectory underscores the substantial unmet medical need in treating androgenic alopecia (搜索), a condition affecting hundreds of millions of men and women worldwide.
Triple Hair Group Inc. (搜索) has positioned itself as a specialized developer of innovative therapies for androgenic alopecia (搜索), with TH07 serving as the company's lead product candidate currently in Phase III clinical development. The company's focus on addressing this widespread dermatological condition through novel therapeutic approaches represents a significant opportunity in the expanding hair loss treatment market.